The 32nd Annual J.P. Morgan Healthcare Conference (January 13-16, 2014 – San Francisco, California, USA): Auxilium Pharmaceuticals.

• Autores: J. Watt
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 50, Nº. 3, 2014, págs. 269-271
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • CEO and President Adrian Adams described Auxilium Pharmaceuticals as "the same as a Big Pharma company, only smaller." This 'specialty biopharmaceutical company' has transformed itself in the last 6 to 9 months to become the "leading men's healthcare franchise with a broad and diverse product portfolio." All of this has led to a very busy 2013, which began with the USD 600 million acquisition (Q2) and integration of Actient Pharmaceuticals, the licensing of avanafil (StendraTM) for erectile dysfunction and ended with the approval of collagenase Clostridium histolyticum (Xiaflex®) in Peyronie's disease. From a portfolio of 2 products at the beginning of 2013, Auxilium ended the year with 12.